Skip to content

Study · Non-randomized trial · n = 50 · 1995

1 result

[A comparative evaluation of the efficacy of immunocorrection in children with bronchial asthma living in ecologically contrasted regions].

Trishina SV, Zorin VN, Babin IuF, Trishin SV, Ruban AV, Ruban VV, Skorobatskiĭ VS

Likars'ka sprava1 Jul 1995

PMID8846376 (opens in a new tab)PepBankPUB-08846376
Publisher pageAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In children with bronchial asthma, thymalin's immunomodulating effect was less apparent in ecologically unfavourable regions.

    In plain wordsIn children with asthma, thymalin's immune effect was less apparent in ecologically unfavourable regions than in favourable regions.

    Peptide
    Thymalin
    Outcome
    DecreaseImmunomodulating effect
    Study

    n = 50

    Comparator
    Children in ecologically favourable regions
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    It is in this group of children that immunomodulating effect of thymalin is less apparent.
    2 context sentences
    Summary · context
    Those children residing in unfavourable, in terms of ecological conditions, regions demonstrated diminution of the peripheral blood T-lymphocytes together with a decrease in their functional activity as well as in the activity of interleukin 2.
    Summary · context
    Overall 50 children suffering from infectious-allergic bronchial asthma who live in ecologically contrasting regions were examined.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.